Potter Daniela, Polkinghorne Kevan R, Conway Annie, Davies Christopher E, Au Eric, Pilmore Andrew, Kulkarni Helmant, Roberts Mathew Blake, Kolovos Peter, Dendle Claire, Menahem Solomon, Kotwal Sradha
Department of Renal Medicine, Liverpool Hospital, Liverpool, New South Wales, Australia.
University of New South Wales, Sydney, New South Wales, Australia.
Nephrology (Carlton). 2025 Jul;30(7):e70077. doi: 10.1111/nep.70077.
The COVID-19 pandemic caused widespread global disruptions to healthcare systems. There has been no assessment of this on dialysis practice at a binational level.
A multi-centre retrospective observational cohort study using data from the ANZDATA Registry was performed, with adult incident dialysis patients (1 January 2018 to 31 December 2022). Patients commencing dialysis during 2020-2022 were compared to 2018-2019 for the primary outcome of dialysis incidence rate. Secondary outcomes included estimated glomerular filtration rate (eGFR) at dialysis start, initial treatment location (home vs. facility), modality (haemodialysis vs. peritoneal dialysis), haemodialysis access, frequency, and duration. Commencement during lockdown in 2020-2021 was also analysed.
11 690 patients commenced dialysis during 2020-2022 and 7366 commenced during 2018-2019, with no differences in incidence rate across the pandemic years (2020: p = 0.163, 2021: p = 0.139, 2022: p = 0.190). Compared to pre-pandemic years, uptake of home-based therapies was higher in 2020 (OR = 1.16, 95% CI 1.06-1.27, p = 0.002) with no difference in 2021 and 2022. Peritoneal dialysis uptake was higher in 2020 (OR = 1.15, 95% CI 1.04-1.26, p = 0.005) and 2021 (OR = 1.11, 95% CI 1.01-1.21, p = 0.037) with no difference in 2022. Haemodialysis patients were less likely to commence with an arteriovenous fistula or graft in 2022, compared to pre-pandemic years (OR = 0.87, 95% CI 0.78-0.96, p = 0.005). Odds of commencing haemodialysis with an arteriovenous fistula or graft were reduced during lockdown (OR = 0.79, 95% CI 0.65-0.95, p = 0.014).
There was no change in the incidence rate of dialysis patients during 2020-2022, although there were differences in home dialysis uptake and starting access type.
新冠疫情对全球医疗系统造成了广泛破坏。目前尚无关于其对双边层面透析实践影响的评估。
使用澳大利亚和新西兰透析与移植登记处(ANZDATA Registry)的数据进行了一项多中心回顾性观察队列研究,纳入成年新发透析患者(2018年1月1日至2022年12月31日)。将2020 - 2022年开始透析的患者与2018 - 2019年的患者进行比较,以透析发病率作为主要结局。次要结局包括透析开始时的估计肾小球滤过率(eGFR)、初始治疗地点(家庭 vs. 医疗机构)、治疗方式(血液透析 vs. 腹膜透析)、血液透析通路、频率和持续时间。还分析了2020 - 2021年封锁期间开始透析的情况。
2020 - 2022年有11690例患者开始透析,2018 - 2019年有7366例,疫情期间各年份的发病率无差异(2020年:p = 0.163,2021年:p = 0.139,2022年:p = 0.190)。与疫情前相比,2020年家庭治疗的采用率更高(OR = 1.16,95% CI 1.06 - 1.27,p = 0.002),2021年和2022年无差异。2020年(OR = 1.15,95% CI 1.04 - 1.26,p = 0.005)和2021年(OR = 1.11,95% CI 1.01 - 1.21,p = 0.037)腹膜透析的采用率更高,2022年无差异。与疫情前相比,2022年血液透析患者开始使用动静脉内瘘或移植物的可能性更低(OR = 0.87,95% CI 0.78 - 0.96,p = 0.005)。在封锁期间,使用动静脉内瘘或移植物开始血液透析的几率降低(OR = 0.79,95% CI 0.65 - 0.95,p = 0.014)。
2020 - 2022年期间透析患者的发病率没有变化,尽管家庭透析的采用率和开始透析时的通路类型存在差异。